Inclusion Criteria:

- Histologically proven non-seminomatous germ cell tumour of combined GCT (NSGCT +
seminoma)of the testis

- Histologically proven vascular invasion of the primary tumour into the testicular
veins or lymphatics

- Clinical stage 1 patients (normal AFP and HCG, or optimum marker decline approaching
normal levels after orchidectomy AND no evidence of metastases on CT of chest,
abdomen and pelvis)

- Men aged 16 years or over

- Creatinine clearance > 50 ml/min

- No previous chemotherapy

- WBC > 1.5 x 10^9/l and platelets 100 x 10^9/l

- Fit to receive chemotherapy

- Able to start BEP(500) chemotherapy as part of 111 study within 6* weeks of
orchidectomy

- Written informed consent *If there are unavoidable delays this timescale can be
extended to 8 weeks

Exclusion Criteria:

- All patients with pure seminoma

- All patients with non-seminoma or combined NSGCT + seminoma > stage 1

- All patients with no vascular invasion

- Previous chemotherapy

- Patients with second malignancy except contralateral TIN and contralateral germ cell
tumour treated by orchidectomy and subsequent surveillance of more than 3 years

- Co-morbidity precluding the safe administration of BEP(500) chemotherapy

- Patients with renal function impairment (bilirubin >1.25 x ULN and/or AST >2 x ULN)

- Patients with pre-existing neuropathy

- Patients with pulmonary fibrosis

- Patients with serious illness or medical conditions incompatible with the protocol